AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 143
- Registration Number
- NCT00305448
- Locations
- 🇯🇵
Research Site, Shizuoka, Japan
Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 101
- Registration Number
- NCT00305461
- Locations
- 🇦🇷
Altana Pharma/Nycomed, Tucuman, Argentina
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT00305487
- Locations
- 🇺🇸
Altana Pharma/Nycomed, Milwaukee, Wisconsin, United States
Fast Titration in the Treatment of Schizophrenia, Taiwan
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00304473
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 170
- Registration Number
- NCT00303524
- Locations
- 🇯🇵
Research Site, Utsunomiya, Japan
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
Phase 3
Terminated
- Conditions
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00302770
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 856
- Registration Number
- NCT00300508
- Locations
- 🇦🇹
Research site, Hollabrunn, Austria
🇦🇹Research Site, Zams, Austria
GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00300105
- Locations
- 🇹🇭
Research Site, Bangkok, Thailand
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2008-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT00298688
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1523
- Registration Number
- NCT00297102
- Locations
- 🇬🇧
Altana Pharma/Nycomed Investigational Site, Vale of Glamorgan, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath